About this event
Wednesday March 31st. 2021 - 3pm BST / 4pm CET / 10am EDT
Duration: 45 minutes
Liquid biopsy has the promise to revolutionise cancer care and treatment, allowing the detection of rare cell types with a non-invasive test. It has applications within early cancer detection, ongoing monitoring and the gathering of information where surgical biopsy isn’t an option. One of the biomarkers detected from these tests is circulating cell-free DNA (ctDNA).
The recent Genome UK report, from the UK Government, highlights the latest vision – “to create the most advanced genomic healthcare ecosystem” – with liquid biopsy playing a clear role in this. But how is this technology being used in the NHS?
In this session from the Festival of Genomics and Biodata 2021, you will hear from Mark Kroese, (Director, PHG Foundation), Rachel Butler (Director, South West Genomic Laboratory Hub), Anca Oniscu (Clinical Lead Molecular Pathology, Royal Infirmary of Edinburgh), Nitzan Rosenfeld (Senior Group Leader, Cancer Research UK Cambridge Institute) and Laura Blackburn (Head of Science, PHG Foundation).
This webinar has been made possible with the kind support of our partner, The PHG Foundation.
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events, reports, webinars and digital events, as well as operating a content-rich website.
Share this event